Management and Board of directors
Management and Board of directors
At Hervolution, we challenge biotechnology as we know it by shifting the paradigm in cancer immunotherapy. We have established a great team of scientists, advisors and entrepreneurs with long-standing experience to drive our research every day.
Management Team
Biotech CEO, Company Builder, Inventor. Creative and highly motivated entrepreneur with demonstrated capacity to build a platform company from first innovation to Phase 3 clinical trials – with a focus on maximizing shareholder value creation. Successfully raised >$120M in public and private/VC financing to facilitate rapid growth that includes open INDs with the US FDA and multiple clinical stage assets from Phase 1 to Phase 3 in vaccines and immune-oncology.
Dr. Holst is the founder of Hervolution and has a long-standing experience within immunology and has made pivotal discoveries in these fields. He has taken virus-vectored vaccines further by developing the first clinically effective genetic adjuvants. Peter Holst’s prior inventions are in clinical trials and licensed to GSK.
Board of Directors
Dr. Holst is the founder of Hervolution and has a long-standing experience within immunology and has made pivotal discoveries in these fields. He has taken virus-vectored vaccines further by developing the first clinically effective genetic adjuvants. Peter Holst’s prior inventions are in clinical trials and licensed to GSK.
Scientific Advisory Board
At Hervolution, we challenge biotechnology as we know it by shifting the paradigm in cancer immunotherapy. We have established a great team of scientists, advisors and entrepreneurs with long-standing experience to drive our research every day.
Management Team
Biotech CEO, Company Builder, Inventor. Creative and highly motivated entrepreneur with demonstrated capacity to build a platform company from first innovation to Phase 3 clinical trials – with a focus on maximizing shareholder value creation. Successfully raised >$120M in public and private/VC financing to facilitate rapid growth that includes open INDs with the US FDA and multiple clinical stage assets from Phase 1 to Phase 3 in vaccines and immune-oncology.
Dr. Holst is the founder of Hervolution and has a long-standing experience within immunology and has made pivotal discoveries in these fields. He has taken virus-vectored vaccines further by developing the first clinically effective genetic adjuvants. Peter Holst’s prior inventions are in clinical trials and licensed to GSK.
Board of Directors
Dr. Holst is the founder of Hervolution and has a long-standing experience within immunology and has made pivotal discoveries in these fields. He has taken virus-vectored vaccines further by developing the first clinically effective genetic adjuvants. Peter Holst’s prior inventions are in clinical trials and licensed to GSK.
